Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genetronics' EPT (electroporation therapy) targets head & neck cancer:

This article was originally published in Clinica

Executive Summary

Positive trial results supporting Genetronics Biomedical's electroporation therapy have shown that the system successfully treated 83% of patients who were diagnosed primary head and neck cancer. A four-week follow-up of the 12-patient trial revealed that, following treatment with San Diego, California-based Genetronics' proprietary electroporation system, tissue excisions from ten of the patients showed no evidence of disease, reports study leader Martin Burian, of the University of Vienna.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts